126 related articles for article (PubMed ID: 35377239)
21. A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Takei J; Kaneko MK; Ohishi T; Kawada M; Harada H; Kato Y
Oncol Lett; 2020 Apr; 19(4):2809-2816. PubMed ID: 32218834
[TBL] [Abstract][Full Text] [Related]
22. Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Hosono H; Takei J; Ohishi T; Sano M; Asano T; Sayama Y; Nakamura T; Yanaka M; Kawada M; Harada H; Kaneko MK; Kato Y
Int J Mol Med; 2020 Oct; 46(4):1443-1452. PubMed ID: 32945346
[TBL] [Abstract][Full Text] [Related]
23. A cancer-specific anti-podocalyxin monoclonal antibody (60-mG
Kaneko MK; Ohishi T; Kawada M; Kato Y
Biochem Biophys Rep; 2020 Dec; 24():100826. PubMed ID: 33088928
[TBL] [Abstract][Full Text] [Related]
24. A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Takei J; Kaneko MK; Ohishi T; Hosono H; Nakamura T; Yanaka M; Sano M; Asano T; Sayama Y; Kawada M; Harada H; Kato Y
Oncol Rep; 2020 Nov; 44(5):1949-1960. PubMed ID: 33000243
[TBL] [Abstract][Full Text] [Related]
25. Antitumor activities of a defucosylated anti‑EpCAM monoclonal antibody in colorectal carcinoma xenograft models.
Li G; Suzuki H; Ohishi T; Asano T; Tanaka T; Yanaka M; Nakamura T; Yoshikawa T; Kawada M; Kaneko MK; Kato Y
Int J Mol Med; 2023 Feb; 51(2):. PubMed ID: 36660940
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Drug Conjugates Using Mouse-Canine Chimeric Anti-Dog Podoplanin Antibody Exerts Antitumor Activity in a Mouse Xenograft Model.
Kato Y; Ito Y; Ohishi T; Kawada M; Nakamura T; Sayama Y; Sano M; Asano T; Yanaka M; Okamoto S; Handa S; Komatsu Y; Takei J; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2020 Apr; 39(2):37-44. PubMed ID: 32182186
[TBL] [Abstract][Full Text] [Related]
27. Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
Yoneda H; Mitsuhashi A; Yoshida A; Ogino H; Itakura S; Nguyen NT; Nokihara H; Sato S; Shinohara T; Hanibuchi M; Abe S; Kaneko MK; Kato Y; Nishioka Y
Cancer Sci; 2024 Feb; 115(2):357-368. PubMed ID: 38148492
[TBL] [Abstract][Full Text] [Related]
28. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
29. Antiglycopeptide Mouse Monoclonal Antibody LpMab-21 Exerts Antitumor Activity Against Human Podoplanin Through Antibody-Dependent Cellular Cytotoxicity and Complement-Dependent Cytotoxicity.
Kato Y; Kunita A; Fukayama M; Abe S; Nishioka Y; Uchida H; Tahara H; Yamada S; Yanaka M; Nakamura T; Saidoh N; Yoshida K; Fujii Y; Honma R; Takagi M; Ogasawara S; Murata T; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2017 Feb; 36(1):20-24. PubMed ID: 28234556
[TBL] [Abstract][Full Text] [Related]
30. Establishment of P38Bf, a Core-Fucose-Deficient Mouse-Canine Chimeric Antibody Against Dog Podoplanin.
Kato Y; Mizuno T; Yamada S; Nakamura T; Itai S; Yanaka M; Sano M; Kaneko MK
Monoclon Antib Immunodiagn Immunother; 2018 Nov; 37(5):218-223. PubMed ID: 30362926
[TBL] [Abstract][Full Text] [Related]
31. An anti‑TROP2 monoclonal antibody TrMab‑6 exerts antitumor activity in breast cancer mouse xenograft models.
Tanaka T; Ohishi T; Asano T; Takei J; Nanamiya R; Hosono H; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Jul; 46(1):. PubMed ID: 34013368
[TBL] [Abstract][Full Text] [Related]
32. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
[TBL] [Abstract][Full Text] [Related]
33. A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models.
Suzuki H; Ohishi T; Kaneko MK; Kato Y
Cancers (Basel); 2023 Oct; 15(20):. PubMed ID: 37894446
[TBL] [Abstract][Full Text] [Related]
34. Anti‑HER3 monoclonal antibody exerts antitumor activity in a mouse model of colorectal adenocarcinoma.
Asano T; Ohishi T; Takei J; Nakamura T; Nanamiya R; Hosono H; Tanaka T; Sano M; Harada H; Kawada M; Kaneko MK; Kato Y
Oncol Rep; 2021 Aug; 46(2):. PubMed ID: 34184091
[TBL] [Abstract][Full Text] [Related]
35. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity.
Kaneko MK; Yamada S; Nakamura T; Abe S; Nishioka Y; Kunita A; Fukayama M; Fujii Y; Ogasawara S; Kato Y
Cancer Med; 2017 Apr; 6(4):768-777. PubMed ID: 28332312
[TBL] [Abstract][Full Text] [Related]
36. A defucosylated anti-CD317 antibody exhibited enhanced antibody-dependent cellular cytotoxicity against primary myeloma cells in the presence of effectors from patients.
Ishiguro T; Kawai S; Habu K; Sugimoto M; Shiraiwa H; Iijima S; Ozaki S; Matsumoto T; Yamada-Okabe H
Cancer Sci; 2010 Oct; 101(10):2227-33. PubMed ID: 20701608
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic antitumor efficacy of anti-epidermal growth factor receptor antibody, cetuximab, against malignant pleural mesothelioma.
Kurai J; Chikumi H; Hashimoto K; Takata M; Sako T; Yamaguchi K; Kinoshita N; Watanabe M; Touge H; Makino H; Igishi T; Hamada H; Yano S; Shimizu E
Int J Oncol; 2012 Nov; 41(5):1610-8. PubMed ID: 22922885
[TBL] [Abstract][Full Text] [Related]
38. The mouse-canine chimeric anti-dog podoplanin antibody P38B exerts antitumor activity in mouse xenograft models.
Kato Y; Ohishi T; Kawada M; Maekawa N; Konnai S; Itai S; Yamada S; Kaneko MK
Biochem Biophys Rep; 2019 Mar; 17():23-26. PubMed ID: 30519645
[TBL] [Abstract][Full Text] [Related]
39. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
40. Generation and characterization of a target-selectively activated antibody against epidermal growth factor receptor with enhanced anti-tumor potency.
Yang Y; Guo Q; Xia M; Li Y; Peng X; Liu T; Tong X; Xu J; Guo H; Qian W; Hou S; Dai J; Wang H; Liu R; Guo Y
MAbs; 2015; 7(2):440-50. PubMed ID: 25679409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]